Dou et al., 2021 - Google Patents
The immune landscape of Chinese head and neck adenoid cystic carcinoma and clinical implicationDou et al., 2021
View HTML- Document ID
- 7660534200799636347
- Author
- Dou S
- Li R
- He N
- Zhang M
- Jiang W
- Ye L
- Yang Y
- Zhao G
- Yang Y
- Li J
- Chen D
- Zhu G
- Publication year
- Publication venue
- Frontiers in Immunology
External Links
Snippet
Novel systemic agents and effective treatment strategies for recurrence adenoid cystic carcinoma (ACC) of the head and neck are still worthy of further exploration. Here, we analyzed the mutations and expression profiles of 75 Chinese ACC patients, characterized …
- 208000002517 Adenoid Cystic Carcinoma 0 title abstract description 102
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhu et al. | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma | |
Chocarro de Erauso et al. | Resistance to PD-L1/PD-1 blockade immunotherapy. A tumor-intrinsic or tumor-extrinsic phenomenon? | |
Lim et al. | The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma | |
Arora et al. | Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors | |
Hodi et al. | TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma | |
Genova et al. | Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade | |
Lee et al. | Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition | |
Daniels et al. | Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas | |
Jessurun et al. | Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review | |
Leruste et al. | Clonally expanded T cells reveal immunogenicity of rhabdoid tumors | |
Friedman et al. | Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study | |
Conforti et al. | Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion | |
Kemp et al. | Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages | |
Lo et al. | Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses | |
Wang et al. | Mechanism of immune evasion in breast cancer | |
Dou et al. | The immune landscape of Chinese head and neck adenoid cystic carcinoma and clinical implication | |
Weeden et al. | Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer | |
Soulieres et al. | Molecular alterations and buparlisib efficacy in patients with squamous cell carcinoma of the head and neck: biomarker analysis from BERIL-1 | |
Galsky et al. | Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer | |
Alvarez-Prado et al. | Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors | |
Wang et al. | Progression of EGFR-mutant lung adenocarcinoma is driven by alveolar macrophages | |
Raskova Kafkova et al. | NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy | |
Iafolla et al. | Predicting toxicity and response to pembrolizumab through germline genomic HLA class 1 analysis | |
Huang et al. | Identification of immune-related subtypes and characterization of tumor microenvironment infiltration in bladder cancer | |
Sun et al. | Construction of a promising tumor-infiltrating CD8+ T cells gene signature to improve prediction of the prognosis and immune response of uveal melanoma |